OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:50 UTC. Every row links to its source record.

LPAR6 lysophosphatidic acid receptor 6

ENSG00000139679 · protein coding · Open Targets profile

Binds to oleoyl-L-alpha-lysophosphatidic acid (LPA). Intracellular cAMP is involved in the receptor activation. Important for the maintenance of hair growth and texture. .

In 12 of 15 cancers, the evidence for LPAR6 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751retinoblastomaretinoblastomaretinoblastoma: somatic 0.91retinoblastoma: germline 0.95urinary bladder cancerurinary bladder cancerurinary bladder cancer: somatic 0.78urinary bladder cancer: germline 0.87urinary bladder carcinomaurinary bladder carcinomaurinary bladder carcinoma: somatic 0.78urinary bladder carcinoma: germline 0.87hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.94hereditary retinoblastomahereditary retinoblastomahereditary retinoblastoma: germline 0.92bone osteosarcomabone osteosarcomabone osteosarcoma: germline 0.84small cell lung carcinomasmall cell lung carcinomasmall cell lung carcinoma: germline 0.84Lynch syndromeLynch syndromeLynch syndrome: germline 0.65lung adenocarcinomalung adenocarcinomalung adenocarcinoma: somatic 0.56ovarian cancerovarian cancerovarian cancer: germline 0.57squamous cell carcinomasquamous cell carcinomasquamous cell carcinoma: somatic 0.56trilateral retinoblastomatrilateral retinoblastomatrilateral retinoblastoma: germline 0.55ovarian neoplasmovarian neoplasmovarian neoplasm: germline 0.19hepatocellular carcinomahepatocellular carcinomabenign urinary system neoplasmbenign urinary system neoplasmbenign urinary system neoplasm: germline 0.16

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, High-Quality Ligand, Druggable Family
Antibody
UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
PROTAC
Small Molecule Binder

gnomAD loss of function constraint: o/e 0.7735300064086914 (upper bound 1.1603000164031982). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of LPAR6's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of LPAR6's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.